Foreign-Trade Zone (FTZ) 7; Authorization of Production Activity; AbbVie Ltd.; (Pharmaceutical Products); Barceloneta, Puerto Rico
---
identifier: "/us/fr/2023-18466"
source: "fr"
legal_status: "authoritative_unofficial"
title: "Foreign-Trade Zone (FTZ) 7; Authorization of Production Activity; AbbVie Ltd.; (Pharmaceutical Products); Barceloneta, Puerto Rico"
title_number: 0
title_name: "Federal Register"
section_number: "2023-18466"
section_name: "Foreign-Trade Zone (FTZ) 7; Authorization of Production Activity; AbbVie Ltd.; (Pharmaceutical Products); Barceloneta, Puerto Rico"
positive_law: false
currency: "2023-08-28"
last_updated: "2023-08-28"
format_version: "1.1.0"
generator: "[email protected]"
agency: "Commerce Department"
document_number: "2023-18466"
document_type: "notice"
publication_date: "2023-08-28"
agencies:
- "Commerce Department"
- "Foreign-Trade Zones Board"
fr_citation: "88 FR 58544"
fr_volume: 88
docket_ids:
- "B-30-2023"
---
# Foreign-Trade Zone (FTZ) 7; Authorization of Production Activity; AbbVie Ltd.; (Pharmaceutical Products); Barceloneta, Puerto Rico
On April 25, 2023, AbbVie Ltd., submitted a notification of proposed production activity to the FTZ Board for its facility within Subzone 7I, in Barceloneta, Puerto Rico.
The notification was processed in accordance with the regulations of the FTZ Board (15 CFR part 400), including notice in the *Federal Register* inviting public comment (88 FR 27860—27861, May 3, 2023). On August 23, 2023, the applicant was notified of the FTZ Board's decision that no further review of the activity is warranted at this time. The production activity described in the notification was authorized, subject to the FTZ Act and the FTZ Board's regulations, including section 400.14.
Dated: August 23, 2023.
Elizabeth Whiteman,
Executive Secretary.